Semin Oncol. 2015 Oct;42 Suppl 2:S11-8. doi: 10.1053/j.seminoncol.2015.09.019. Epub 2015 Sep 11.

Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.

Garon EB1.

Author information

• 1Director of Thoracic Oncology Program, Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, CA. Electronic address: egaron@mednet.ucla.edu.

Abstract

In non-small cell lung cancer (NSCLC), the first immune checkpoint inhibitor to be approved by the US Food and Drug Administration was nivolumab, based on a survival advantage over docetaxel in recurrent squamous NSCLC, a difficult-to-treat histology. In addition, several other immune checkpoint inhibitors are also in late-stage development. Most of these agents inhibit the programmed cell death protein 1 (PD-1) pathway, targeting either the PD-1 receptor or its ligand, programmed cell death ligand 1 (PD-L1). In addition to nivolumab, pembrolizumab is a PD-1 inhibitor under investigation in NSCLC, and atezolizumab (MPDL3280A), durvalumab (MEDI4736), and avelumab (MSB0010718C) are PD-L1 inhibitors under investigation. The cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) immune checkpoint inhibitors ipilimumab and tremelimumab are also under investigation in NSCLC, largely as part of combination approaches rather than as monotherapy. PD-L1 expression as a potential biomarker to select patients most likely to respond to inhibitors of the PD-1 pathway has been widely studied.